Tapinarof Cream 1% Once Daily: Consistent Efficacy Across Age Groups for Children Down to 2 Years of Age with Atopic Dermatitis in Two Pivotal Phase 3 Trials
Main Article Content
Keywords
tapinarof cream 1% once daily, atopic dermatiits, Tapinarof
Abstract
- Tapinarof (VTAMA®, Dermavant Sciences, an Organon Company) is a non-steroidal, topical aryl hydrocarbon receptor (AhR) agonist approved by the FDA for the treatment of atopic dermatitis (AD) in adults and children down to 2 years of age, and for the treatment of plaque psoriasis in adults, with no warnings, contraindications, drug–drug interactions, or restrictions on duration, location, or extent of use1
- Tapinarof cream is cosmetically elegant, easily applied, quickly absorbed, and not greasy or sticky2
- Tapinarof binds to and activates AhR to restore the skin barrier by upregulating key barrier
components, downregulating pro-inflammatory cytokines associated with AD, and reducing oxidative
stress (Figure 1)3
- In ADORING 1 and 2, two pivotal phase 3, randomized, double-blind, vehicle-controlled trials, tapinarof cream 1% once daily (QD) demonstrated statistically significant efficacy and was well tolerated in adults and children down to 2 years of age with AD4
References
2. Bagel J, et al. J Am Acad Dermatol. 2023;89:936–944.
3. Eichenfield LF, et al. J Dermatolog Treat. 2024;35:2300354.
4. Silverberg JI, et al. J Am Acad Dermatol. 2024;91:457–465.
5. Stein Gold L, et al. J Dermatolog Treat. 2025;36:2444489.
6. Bissonnette R, et al. J Am Acad Dermatol. 2025;93:707–714.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.